NASDAQ:MBRX Moleculin Biotech Q3 2025 Earnings Results & Report $6.83 -0.31 (-4.34%) Closing price 03:59 PM EasternExtended Trading$6.96 +0.14 (+1.98%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Moleculin Biotech beat analyst earnings expectations in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$2.60 versus the -$4.00 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 13, 2025TimeBefore Market OpensConference Call7:00 AM ET Moleculin Biotech EPS ResultsActual EPS-$2.60Consensus EPS -$4.00Beat/MissBeat by +$1.40One Year Ago EPSN/AEPS Beat Rate2 of last 4 quartersMoleculin Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) Moleculin Biotech Q3 2025 Earnings FAQ Did Moleculin Biotech beat earnings estimates for Q3 2025? Moleculin Biotech (NASDAQ:MBRX) reported earnings of -$2.60 per share for Q3 2025, beating the consensus estimate of -$4.00. The report was announced on Thursday, November 13, 2025. Moleculin Biotech Earnings HeadlinesMoleculin Reports Q3 Results; Completes MIRACLE Trial Treatment With Data Expected In Q1 2027November 16 at 4:03 PM | rttnews.comMoleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data ReadoutNovember 16 at 7:30 AM | globenewswire.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 17 at 1:00 AM | Weiss Ratings (Ad)Moleculin Secures Australian Patent for Annamycin Formulation TechnologyNovember 12, 2026 | globenewswire.comPreclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with ImmunotherapiesNovember 10, 2026 | globenewswire.comMoleculin Biotech (NASDAQ:MBRX) Stock Gets Downgrade from Wall Street ZenNovember 7, 2026 | americanbankingnews.comSee More Moleculin Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Moleculin Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Moleculin Biotech and other key companies, straight to your email. Email Address About Moleculin BiotechMoleculin Biotech (NASDAQ:MBRX) is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing treatments for cancer and other serious diseases. Its research centers on drug candidates intended to address cancers that can be difficult to treat with existing therapies. The company’s pipeline includes Annamycin, an investigational anthracycline being studied for acute myeloid leukemia and soft-tissue sarcoma that has spread to the lungs. Moleculin has described Annamycin as designed to avoid some limitations associated with older anthracyclines, including heart-related toxicity. Another candidate, WP1066, is an investigational immunotherapy designed to inhibit STAT3, a protein involved in tumor growth and immune response. It is being explored for brain tumors, including glioblastoma. Moleculin is led by co-founder and Chief Executive Officer Walter Klemp. Its drug candidates remain investigational and are not approved for commercial use.View Moleculin Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.